Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer

Journal of Clinical Oncology

Volumn 26, Issue 10, 2008, Pages 1691-1697

  Puhalla, Shannon ^a   Mrozek, Ewa ^a   Young, Donn ^a   Ottman, Susan ^a   McVey, Anne ^a   Kendra, Kari ^a   Merriman, Nancy J ^a   Knapp, Mark ^a   Patel, Taral ^a   Thompson, Mark E ^a   Maher, James F ^a   Moore, Timothy D ^a   Shapiro, Charles L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; TAXOID;

ABDOMINAL PAIN; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANEMIA; ARTICLE; AXILLARY LYMPH NODE; BLOOD TRANSFUSION; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG MECHANISM; EDEMA; EYE DISEASE; EYE TEARING; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL CHANGES; NAIL DISEASE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; SEPSIS; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VOMITING; AXILLA; BREAST TUMOR; DOSE RESPONSE; FEMALE; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; TAXOIDS;

EID: 43249118257     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.3941     Document Type: Article

References (46)

1. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
2. Mamounas EP, Bryant J, Lembersky B, et al: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. J Clin Oncol 23:3686-3696, 2005
3. Martin M, Pienkowski T, Mackey J, et al: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313, 2005
4. Roche H, Fumoleau P, Spielmann M, et al: Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 24:5664-5671, 2006
5. Sackett D, Haynes RB, Tugwell P: Clinical Epidemiology: A Basic Science for Clinicians. New York, NY, Lippincott Williams & Wilkins, 1985, pp 171-197
6. Khayat D, Chollet P, Antoine EC, et al: Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 19:3367-3375, 2001
7. Perez EA, Geeraerts L, Suman VJ, et al: A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol 13:1225-1235, 2002
8. Spielmann M, Tubiana-Hulin M, Namer M, et al: Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: A randomised phase II trial. Br J Cancer 86:692-697, 2002
9. Paridaens R, Van Aelst F, Georgoulias V, et al: A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. Ann Oncol 14:433-440, 2003
10. Cresta S, Grasselli G, Mansutti M, et al: A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann Oncol 15:433-439, 2004
11. Anton A, Hornedo J, Lluch A, et al: A phase II study of sequential docetaxel followed by doxorubicin/cyclophosphamide as first-line chemotherapy for metastatic breast cancer. Clin Breast Cancer 4:286-291, 2003
12. Gradishar WJ, Wedam SB, Jahanzeb M, et al: Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer. Ann Oncol 16:1297-1304, 2005
13. Ramaswamy B, Povoski SP, Rhoades C, et al: Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer. Breast Cancer Res Treat 93:67-74, 2005
14. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163-169, 1986
15. Norton L: A Gompertzian model of human breast cancer growth. Cancer Res 48:7067-7071, 1988
16. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial C9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003.09.081, 2003
17. Hudis CA, Citron M, Berry D: Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. Breast Cancer Res Treat 94:S20, 2005 (suppl 1; abstr 41)
18. Carlson RW, Anderson BO, Burstein HJ, et al: Invasive breast cancer. J Natl Compr Canc Netw 5:246-312, 2007
19. Miller KD, McCaskill-Stevens W, Sisk J, et al: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 17:3033-3037, 1999
20. Piedbois P, Serin D, Priou F, et al: Dose-dense adjuvant chemotherapy in node-positive breast cancer: Docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks: AERO B03 randomized phase II study. Ann Oncol 18:52-57, 2007
21. Kummel S, Thomas A, Paepke S, et al: Primary systemic chemotherapy with sequential, dosedense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: A phase II study. Acta Oncol 44:248-254, 2005
22. Cooper BW, Radivoyevitch T, Overmoyer BA, et al: Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer. Breast Cancer Res Treat 97:311-318, 2006
23. Lambert-Falls R, Modugno S: Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study. Clin Breast Cancer 7:697-704, 2007
24. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
25. Liu PY, LeBlanc M: Desai: False positive rates of randomized phase II trials. Control Clin Trials 20:343-352, 1999
26. Miller KD, Soule SE, Calley C, et al: Randomized phase II trial of the anti-angiogenic potential of doxorubicin and docetaxel: Primary chemotherapy as biomarker discovery laboratory. Breast Cancer Res Treat 89:187-197, 2005
27. Sparano J, Wang S, Martino S, et al: Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup trial E1199. J Clin Oncol 25:516, 2007
28. Cleeland CS, Mendoza TR, Wang XS, et al: Assessing symptom distress in cancer patients: The M.D. Anderson Symptom Inventory. Cancer 89: 1634-1646, 2000
29. Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34:13-19, 1997
30. Guo B, Villeneuve DJ, Hembruff SL, et al: Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Breast Cancer Res Treat 85:31-51, 2004
31. Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organisation for Research and Treatment of Cancer randomized study with cross-over. J Clin Oncol 18:724-733, 2000
32. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as frontline chemotherapy for metastatic breast cancer: An Intergroup trial (E1193). J Clin Oncol 21:588-592, 2003
33. Chang JC, Wooten EC, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369, 2003
34. Iwao-Koizumi K, Matoba R, Ueno N, et al: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23:422-431, 2005
35. Sotiriou C, Powles TJ, Dowsett M, et al: Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4:R3, 2002
36. Folgueira MA, Carraro DM, Brentani H, et al: Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 11:7434-7443, 2005
37. Cleator S, Tsimelzon A, Ashworth A, et al: Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat 95:229-233, 2006
38. Gianni L, Zambetti M, Clark K, et al: Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265-7277, 2005
39. Mina L, Soule SE, Badve S, et al: Predicting response to primary chemotherapy: Gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat 103:197-208, 2007
40. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
41. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685, 2005
42. Modlich O, Prisack H-B, Munnes M, et al: Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 10:6418-6431, 2004
43. Chang JC, Wooten EC, Tsimelzon A, et al: Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol 23:1169-1177, 2005
44. Bosch TM, Huitema ADR, Doodeman VD, et al: Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 12:5786-5793, 2006
45. Lewis LD, Miller AA, Rosner GL, et al: A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res 13:3302-3311, 2007
46. National Surgical Adjuvant Breast and Bowel Project: Nearly 50 years of clinical trial history. www.nsabp.pitt.edu